Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease
Manage episode 298084855 series 2857008
由Player FM以及我们的用户群所搜索的PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education — 版权由出版商所拥有，而不是Player FM，音频直接从出版商的伺服器串流. 点击订阅按钮以查看Player FM更新，或粘贴收取点链接到其他播客应用程序里。
Go online to PeerView.com/YFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses new evidence from ASCO 2021 on the continuing integration of immunotherapy, targeted agents, and novel therapeutics across a wide range of renal cell carcinoma settings. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.